Talzenna-Xtandi Combination Improves Time to Disease Progression in Metastatic Prostate Cancer

Published on: 

Talzenna Plus Xtandi lengthened time to progression in men with metastatic castration-resistant prostate cancer.

Adding Talzenna (talazoparib) to Xtandi (enzalutamide) improved the length of time men with metastatic castration-resistant prostate cancer lived before their disease worsened, compared to those who were treated with Xtandi plus a placebo, according to findings from the phase 3 TALAPRO-2 clinical trial.

The results showed that the Talzenna-containing regimen lengthened time until disease progression was seen on scans — known as radiographic progression-free survival — in patients with the disease, regardless of their homologous recombination repair (HRR) gene mutation status.

“We are very pleased with the strong findings from TALAPRO-2, and although no definitive conclusions can be made across trials, the (radiographic progression-free survival) appears to be the longest observed in a randomized trial in this setting,” Dr. Chris Boshoff, chief development officer in Oncology and Rare Disease at Pfizer Global Product Development (the manufacturer of Talzenna), said in a press release.

Talzenna, which was approved by the Food and Drug Administration to treat metastatic breast cancer, is a PARP inhibitor that works by inhibiting certain proteins that aid in repairing damaged DNA in cancer cells. By doing so, the cells cannot continue to thrive and reproduce.

Findings from TALAPRO-2 also showed a trend toward improved overall survival (time from treatment until death by any cause), though those data are not yet mature enough to draw any conclusions.

“These data highlight the potential for Talzenna in combination with Xtandi, if approved, to become a new standard of care for (metastatic castration-resistant prostate cancer), irrespective of HRR gene mutation status,” Boshoff concluded.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.